Compare Godaddy Inc (GDDY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Godaddy Inc trades at $103.39 (market cap $13.05B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Godaddy Inc is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 65 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GDDY | SYRE | |
|---|---|---|
Market Cap | $13.05B | $7.52B |
Volume | 1,123,303 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $135.18 | $108.92 |
52-Week Low | $75.07 | $22.18 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $15.73B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $103.36, up 1.02% today, with a bullish technical signal from moving averages. The company reported revenue of $4.95B in 2025 and net income of $875M, with consistent earnings beats in recent quarters. However, the stock faces headwinds from a securities class action lawsuit alleging misrepresentations about domain contract terms, as reported by multiple law firms in late September 2026.
The outlook is mixed: strong profitability and earnings momentum support upside, but legal risks and a consensus price target below the current price suggest caution. Investors should weigh robust fundamentals against litigation overhangs and monitor Q3 2026 earnings for further direction.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
